Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Bruce, Coate"'
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 17 (2024)
Background: More than half of patients with Parkinson’s disease will experience psychosis symptoms in the form of hallucinations or delusions at some point over the course of their disease. These symptoms can significantly impact patients’ health
Externí odkaz:
https://doaj.org/article/3b0df1a440874b68a9dd8f87031e7f60
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
BackgroundPimavanserin, a selective 5-HT2A inverse agonist/antagonist, is the only treatment approved by the US Food and Drug Administration for hallucinations and delusions associated with Parkinson's disease (PD) psychosis.AimWe aimed to evaluate m
Externí odkaz:
https://doaj.org/article/895728bd476845e8ab214aa5f5e0e4af
Autor:
Clive Ballard, Jeffrey Cummings, Pierre N Tariot, Sanjeev Pathak, Bruce Coate, Srdjan Stankovic
Alzheimer’s disease psychosis (ADP) is a common and serious condition with substantial unmet need for safe and effective treatments. Pimavanserin is approved in the US to treat Parkinson’s disease hallucinations and delusions. This post-hoc analy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a305f7d75712ff86a83bc0d0761c79d
https://doi.org/10.1101/2022.08.11.22278482
https://doi.org/10.1101/2022.08.11.22278482
Publikováno v:
Journal of Parkinson's Disease
Background: Parkinson’s disease psychosis (PDP) is a common nonmotor symptom that affects up to 60% of patients. Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, is approved for treating hallucinations and delusions associated with PDP.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb1e25e11be37e8e2f0a08882201fa0c
https://doi.org/10.3233/jpd-202047
https://doi.org/10.3233/jpd-202047
Publikováno v:
International Journal of Geriatric Psychiatry. 35:1402-1408
OBJECTIVES Patients with Alzheimer's disease psychosis (ADP) commonly experience concomitant agitation and aggression. We investigated whether a reduction in ADP following pimavanserin treatment conferred a reduction in associated agitation and aggre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72af2453152f2e8ef0604c9e54628f52
https://doi.org/10.1002/gps.5381
https://doi.org/10.1002/gps.5381
Autor:
Victor Abler, Marc Cantillon, Jason L. Aldred, Lori Jacobi, Gustavo Alva, James C. Norton, Daryl DeKarske, Rene Nunez, Bruce Coate
Publikováno v:
Journal of Parkinson's Disease
Background: Many patients with Parkinson’s disease (PD) experience depression. Objective: Evaluate pimavanserin treatment for depression in patients with PD. Methods: Pimavanserin was administered as monotherapy or adjunctive therapy to a selective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bde8bb7f1da2492cfaadc2f244aabb1
https://pubmed.ncbi.nlm.nih.gov/32804101
https://pubmed.ncbi.nlm.nih.gov/32804101
Autor:
Hubert H. Fernandez, Tihomir V. Ilić, James C. Norton, David L Kreitzman, Srdjan Stankovic, Jean-Philippe Azulay, Stuart Isaacson, Clive Ballard, Bruce Coate, Victor Abler, Joaquim J. Ferreira
Publikováno v:
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
Introduction: Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, was approved for hallucinations and delusions associated w
Introduction: Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, was approved for hallucinations and delusions associated w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3e9bd59836a830420547e27197b6fc6
https://pubmed.ncbi.nlm.nih.gov/33933853
https://pubmed.ncbi.nlm.nih.gov/33933853
Autor:
Thomas Kakuda, Vanitha Sekar, Peter Vis, Bruce Coate, Robert Ryan, David Anderson, Guy De La Rosa, Joseph Mrus
Publikováno v:
AIDS Research and Treatment, Vol 2012 (2012)
Objectives. Evaluation of pharmacokinetics and pharmacodynamics of darunavir and etravirine among HIV-1–infected, treatment-experienced adults from GRACE, by sex and race. Methods. Patients received darunavir/ritonavir 600/100mg twice daily plus ot
Externí odkaz:
https://doaj.org/article/69d57b1edb1e4c86a84e063601f34ea0
Autor:
Doral Fredericks, Clive Ballard, Alberto J. Espay, Candace Andersson, Michael T. Guskey, Bruce Coate, Stewart A. Factor, Niccole J. Larsen, James C. Norton, Joseph H. Friedman, Joaquin A. Vizcarra, Daniel Weintraub, Anthony E. Lang
Publikováno v:
Movement Disorders. 33:1769-1776
Background: PD psychosis is often associated with cognitive impairment, including dementia, and involves dopaminergic, serotonergic, and cholinergic mechanisms. Objective: To evaluate the differential effect of the antipsychotic pimavanserin, a selec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1d8d89cb1305a4edd030d0b54ab0001b
https://doi.org/10.1002/mds.27488
https://doi.org/10.1002/mds.27488
Autor:
Zunera Khan, Mustabshira A Qayyum, Jeffrey L. Cummings, Polychronis Kemos, Joanne McDermid, James M. Youakim, Clive Ballard, Carol Banister, Ingelin Testad, Kayleigh Nunez, Randall Owen, Delik Ocal, George Demos, Elaine B Tomkinson, Maria Megalogeni, Bruce Coate, Anya Petrava, Ella V Brookes, Srdjan Stankovic, Miguel Vasconcelos Da Silva, Olga Borejko
Publikováno v:
The Lancet Neurology. 17:213-222
Pimavanserin is a selective 5-HTWe did a phase 2, randomised, double-blind, placebo-controlled, single-centre (with multiple affiliated nursing home sites across the UK) study. We included participants of either sex who were aged 50 years or older wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e45c55f813d56e414a3282861191c4ce
https://doi.org/10.1016/s1474-4422(18)30039-5
https://doi.org/10.1016/s1474-4422(18)30039-5